Erlotinib for the treatment of relapsed non-small cell lung cancer

Erlotinib for the treatment of relapsed non-small cell lung cancer

Bibliographic Details
Main Authors:	C McLeod, A Bagust, A Boland, J Hockenhull, Y Dundar, C Proudlove, H Davis, J Green, F Macbeth, J Stevenson, T Walley, R Dickson
Format:	Article
Language:	English
Published:	NIHR Journals Library 2009-06-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta13suppl1/07

Similar Items

Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
by: T Brown, et al.
Published: (2010-10-01)

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation
by: Janette Greenhalgh, et al.
Published: (2015-06-01)

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
by: A Boland, et al.
Published: (2009-09-01)

The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation
by: J Hockenhull, et al.
Published: (2008-04-01)

Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
by: Y Dundar, et al.
Published: (2009-06-01)

Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
by: N Fleeman, et al.
Published: (2010-05-01)

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
by: J Greenhalgh, et al.
Published: (2010-10-01)

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
by: J Greenhalgh, et al.
Published: (2009-10-01)

Rituximab for the treatment of rheumatoid arthritis
by: A Bagust, et al.
Published: (2009-09-01)

Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation
by: Y Dundar, et al.
Published: (2007-01-01)

Drug-eluting stents: a systematic review and economic evaluation
by: R Hill, et al.
Published: (2007-11-01)

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
by: J Greenhalgh, et al.
Published: (2010-05-01)

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation
by: C McLeod, et al.
Published: (2007-08-01)

Systematic review and cost-effectiveness evaluation of ‘pill-in-the-pocket’ strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy
by: C Martin Saborido, et al.
Published: (2010-06-01)

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis
by: J Greenhalgh, et al.
Published: (2011-09-01)

Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation
by: Y Dündar, et al.
Published: (2004-06-01)

Experience with erlotinib in the treatment of non-small cell lung cancer
by: Lorenza Landi, et al.
Published: (2015-08-01)

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation
by: C McLeod, et al.
Published: (2009-01-01)

Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
by: Li W, et al.
Published: (2014-02-01)

Erlotinib in Patients with Brain Metastases for Non-small Cell Lung Cancer
by: Jinming YU, et al.
Published: (2009-12-01)

Progression in Therapy of Erlotinib for Patients with Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2009-12-01)

Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation
by: A. Boland, et al.
Published: (2003-01-01)

Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
by: Jasmine G Lee, et al.
Published: (2012-01-01)

The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
by: N Fleeman, et al.
Published: (2010-01-01)

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation
by: T Brown, et al.
Published: (2013-07-01)

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
by: Yongsheng Wang, et al.
Published: (2012-01-01)

A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer
by: Jinhui TIAN, et al.
Published: (2009-12-01)

The Analysis of Erlotinib on Brain Metastases in Patients with Non-small-cell Lung Cancer
by: Baohui HAN, et al.
Published: (2009-12-01)

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.
by: Kara L Larson, et al.
Published: (2020-01-01)

Role and mechanism of hexokinase 2 in erlotinib resistance in non-small cell lung cancer
by: YOU Qi, et al.
Published: (2020-03-01)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study
by: Auclair Paul L, et al.
Published: (2009-09-01)

Erlotinib in the trentment of Advanced Non-small-cell Lung Cancer: A Systematic Review
by: Yanming TANG, et al.
Published: (2009-12-01)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
by: Boutsikou E, et al.
Published: (2013-03-01)

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
by: William Pao, et al.
Published: (2005-01-01)

The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews
by: C Black, et al.
Published: (2006-01-01)

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
by: Florent Baty, et al.
Published: (2013-01-01)

Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer
by: Yilong WU, et al.
Published: (2009-05-01)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
by: Noem&iacute; Reguart, et al.
Published: (2010-06-01)

Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
by: Haiqing YUAN, et al.
Published: (2009-07-01)

Minocycline-Induced Hyperpigmentation in a Patient Treated with Erlotinib for Non-Small Cell Lung Adenocarcinoma
by: Ann T. Bell, et al.
Published: (2017-02-01)

Cannot write session to /tmp/vufind_sessions/sess_esnl57c5sorfb725879qbu5afg